[go: up one dir, main page]

DK2271668T3 - Adam-15-antistoffer og immunogene peptider - Google Patents

Adam-15-antistoffer og immunogene peptider Download PDF

Info

Publication number
DK2271668T3
DK2271668T3 DK09726165.5T DK09726165T DK2271668T3 DK 2271668 T3 DK2271668 T3 DK 2271668T3 DK 09726165 T DK09726165 T DK 09726165T DK 2271668 T3 DK2271668 T3 DK 2271668T3
Authority
DK
Denmark
Prior art keywords
adam
antibody
antigen
cancer
antibodies
Prior art date
Application number
DK09726165.5T
Other languages
English (en)
Inventor
Salman Rahman
Yatin Patel
Holger Gerhardt
Andrea Emma Lundkvist
Original Assignee
Salman Rahman
Yatin Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salman Rahman, Yatin Patel filed Critical Salman Rahman
Application granted granted Critical
Publication of DK2271668T3 publication Critical patent/DK2271668T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

  1. ADAM-15-ANTISTOFFER OG IMMUNOGENE PEPTIDER Patentkrav
    1. Isoleret antistof eller antigenbindende fragment deraf, der hæmmer ADAM 15-proteaseaktivitet, hvori antistoffet eller det antigenbindende fragment deraf specifikt binder sig til den proteolytiske spalte af metalloprotease-domænet af ADAM 15 og er i stand til at hæmme eller forebygge angiogenese og/eller neovaskularisering, hvori antistoffet eller det antigenbindende fragment deraf ikke er et polyklonalt kaninantistof.
  2. 2. Isoleret antistof eller antigenbindende fragment deraf ifølge krav 1, hvori antistoffet eller det antigenbindende fragment deraf specifikt genkender den proteolytiske spalte af metalloprotease-domænet af ADAM 15 omfattende eller bestående af aminosyresekvensen: IAHELGHSLGLDHD (SEQ ID NO:3), eller et peptid med mindst 90 % sekvensidentitet med SEQ ID NO: 3.
  3. 3. Isoleret antistof eller antigenbindende fragment deraf ifølge enten krav 1 eller krav 2, hvori antistoffet eller det antigenbindende fragment deraf: a) specifikt binder sig til en epitop på humant ADAM 15-polypeptid defineret ved aminosyre 346-359 af SEQ ID NO: 1, fremlagt i figur 8; eller b) specifikt binder sig til en epitop på humant ADAM 15-polypeptid omfattende den topografiske region His352, Ser353, Leu354, Gly355, Leu356, Asp357 og Asp359; eller c) specifikt binder sig til en epitop på humant ADAM 15-polypeptid omfattende den topografiske region Leu354, Gly355, Leu356, Asp357, His358 og Asp359; d) er et immunoglobulin eller andet molekyle, der omfatter mindst et antigenbindende domæne, eller e) er et muse-, rotte-, kanin-, gede-, æsel-, fåre-, humaniseret, humant, rekombinant eller syntetisk antistof eller et antigenbindende fragment deraf udvalgt fra en Fab, Fab’ F(ab’)2, scFv, Fv, ds- Fv, ds-scFv eller omfatter et antigenbindende domæne, der udviser antigenbindende funktion, og multimerer deraf og bispecifikke antistoffragmenter; eller f) er i stand til at: (i) hæmme aktiveringen af Akt-kinasen, (ii) hæmme phosphorylering af glycogensynthasekinase 3β (GSK 3β) i endothelceller og/eller (iii) hæmme angiogenese in vivo ved hæmning af endothelcellers formering og overlevelse.
  4. 4. Isoleret antistof eller et antigenbindende fragment deraf ifølge et hvilket som helst af de foregående krav, hvori antistoffet eller det antigenbindende fragment deraf er et monoklonalt antistof.
  5. 5. Sammensætning omfattende det isolerede antistof eller antigenbindende fragment deraf ifølge et hvilket som helst af de foregående krav til anvendelse i terapi.
  6. 6. Sammensætning omfattende det isolerede antistof eller antigenbindende fragment deraf ifølge et hvilket som helst af kravene 1-4 til anvendelse i in vivo diagnostik.
  7. 7. Sammensætning til anvendelse ifølge krav 5, hvori sammensætningen omfatter en terapeutisk effektiv mængde af en antisense-nukleinsyre og/eller en kort interfererende nukleinsyre (siNA) genereret fra de ADAM 15-specifikke oligonukleotider 5’ AACTCCATCTGTTCTCCTGACTTCCTGTCTC 3’ (SEQ ID NO: 4) som sense-template og 5’ AAAAGTCAGGAGAACAGATGGAGCCTGTTCTC 3’ (SEQ ID NO: 5) som antisense-template, hvori nukleinsyren slår ADAM 15-ekspression ned.
  8. 8. Sammensætning til anvendelse ifølge krav 5 eller krav 7, hvori antistoffet eller det antigenbindende fragment deraf er i en mængde, der er effektiv til at:- - hæmme eller forebygge angiogenese eller neovaskularisering, - behandle cancer, - hæmme endothelcellers formering og/eller glatmuskelcellers formering, - hæmme angiogenese ved hæmning af endothelcellers formering og overlevelse, - hæmme aktivering af Akt-kinasen, - hæmme phosphorylering af glycogensynthasekinase 3 (GSK GSK3P) i endothelceller, - behandle en inflammatorisk tilstand (for eksempel inflammatorisk tarmsygdom, Crohns sygdom, arthritis rheumatoides eller osteoarthritis), - behandle en inflammatorisk karsygdom (for eksempel restenose eller atherosklerose), - behandle aldersrelateret makuladegeneration og/eller akut makuladegeneration, - behandle diabetisk retinopati eller en proliferativ retinopati, - behandle en øjensygdom, såsom retinis pigmentosa, retina-grenveneokklusion, neovaskulært glaukom og Coats sygdom, - forstærke plasminogenaktivering - forebygge proteolytisk spaltning af urokinasereceptor uPAR ved ADAM 15 og/eller - hæmme eller forebygge neovaskularisering og/eller angiogenese i en tumor.
  9. 9. Sammensætning til anvendelse ifølge krav 8, hvori: a) canceren er udvalgt fra gruppen bestående af cervixcancer, uteruscancer, ovariecancer, pancreascancer, nyrecancer, galdeblærecancer, levercancer, hoved- og halscancer, pladecellekarcinom, gastrointestinal cancer, brystcancer (såsom karcinom, duktalt, lobulært og brystvorte-), prostatacancer, testikelcancer, lungecancer, ikke-småcellet lungecancer, non-Hodgkins lymfom, myelomatose, leukæmi (såsom akut lymfatisk leukæmi, kronisk lymfatisk leukæmi, akut myeloid leukæmi og kronisk myeloid leukæmi), hjernecancer (f.eks. astrocytom, glioblastom, medulloblastom), neuroblastom, sarkomer, coloncancer, rectumcancer, mavecancer, analcancer, blærecancer, pancreascancer, endometriecancer, plasmacytom, lymfomer, retinoblastomer, Wilms tumor, Ewing-sarkom, melanom og andre hudcancere; b) canceren er metastatisk karcinom i colon eller rectum; og eventuelt hvor antistoffet eller det antigenbindende fragment deraf er til anvendelse samtidig, separat eller sekventielt med 5-fluororacil og/eller bevacizumab (monoklonalt anti-VEGF-antistof); eller c) canceren er recidiverende eller metastatisk ikke-pladecelle-, ikke-småcellet lungecancer; og eventuelt hvor antistoffet eller det antigenbindende fragment deraf er til anvendelse samtidig, separat eller sekventielt med carboplatin og/eller paclitaxel og/eller bevacizumab (monoklonalt anti-VEGF-antistof).
  10. 10. Peptid til anvendelse i immunisering, hvilket peptid består af aminosyrerne: Xi - IAHELGHSLGLDHD - X2 (SEQ ID NO:8) hvori Xi er en N-terminal-beskyttende gruppe, eventuelt fraværende, X2 er en C-terminal-beskyttende gruppe, eventuelt fraværende, eller et peptid med mindst 90 % sekvensidentitet med SEQ ID NO: 8, hvori peptidet eventuelt er bundet til en bærer, eventuelt i blanding med et eller flere adjuvanser, diluenter og eller hjælpestoffer. 11. peptid ifølge krav 10, hvori den N-terminal-beskyttende gruppe er Ac eller 1-5 aminosyrer.
  11. 12. Peptid ifølge krav 10 eller 11, hvori den C-terminal-beskyttende gruppe er NH2 eller 1-5 aminosyrer.
  12. 13. Nukleinsyremolekyle, der koder for et antistof ifølge et hvilket som helst af kravene 1-4.
  13. 14. Nukleinsyre ifølge krav 10, hvori nukleinsyren er en ekspressions vektor, og eventuelt hvori ekspressionsvektoren er en værtscelle.
  14. 15. Vaccine omfattende peptidet bestående af aminosyrerne: Xi - IAHELGHS LGLDHD - X2 (SEQ ID NO:8) hvori Xi er en N-terminal-beskyttende gruppe, eventuelt fraværende, X2 er en C-terminal-beskyttende gruppe, eventuelt fraværende, eller et peptid med mindst 90 % sekvensidentitet med SEQ ID NO: 8, hvori peptidet eventuelt er bundet til en bærer, eventuelt i blanding med et eller flere adjuvanser, diluenter og eller hjælpestoffer.
DK09726165.5T 2008-03-24 2009-03-24 Adam-15-antistoffer og immunogene peptider DK2271668T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3883708P 2008-03-24 2008-03-24
PCT/IB2009/005613 WO2009118660A2 (en) 2008-03-24 2009-03-24 Adam-15 antibodies and immunogenic peptides

Publications (1)

Publication Number Publication Date
DK2271668T3 true DK2271668T3 (da) 2018-03-05

Family

ID=41114389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09726165.5T DK2271668T3 (da) 2008-03-24 2009-03-24 Adam-15-antistoffer og immunogene peptider

Country Status (4)

Country Link
US (2) US9040049B2 (da)
EP (1) EP2271668B1 (da)
DK (1) DK2271668T3 (da)
WO (1) WO2009118660A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2271668T3 (da) 2008-03-24 2018-03-05 Salman Rahman Adam-15-antistoffer og immunogene peptider
JP5888667B2 (ja) * 2010-04-30 2016-03-22 国立大学法人名古屋大学 Ａｄａｍ作用阻害物質のスクリーニング方法、仮足の保持方法、仮足保持剤、仮足の制御物質のスクリーニング方法、及びａｄａｍ作用阻害剤
EP2621956A2 (en) * 2010-10-01 2013-08-07 Salman Rahman Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications
CN102433388B (zh) * 2012-01-04 2013-03-20 河南科技大学 一种肝癌早期诊断试剂盒
WO2015117199A1 (en) * 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066057A2 (en) 2001-02-23 2002-08-29 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
US6294368B1 (en) * 2001-03-22 2001-09-25 Applera Corporation Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US20040102392A1 (en) 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of ADAM15 expression
WO2004024089A2 (en) * 2002-09-11 2004-03-25 Sloan-Kettering Institute For Cancer Research Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
AU2004221982B2 (en) 2003-03-17 2011-10-13 Km Biologics Co., Ltd. Construct comprising recognition domain of antibody against von Willebrand factor-specific cleaving enzyme
WO2004089294A2 (en) * 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US8604185B2 (en) * 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
ES2313841B1 (es) 2007-06-26 2010-01-12 Proyecto De Biomedicina Cima, S.L. Composiciones para tratamiento anti-fibrinolitico.
WO2009008414A1 (ja) 2007-07-10 2009-01-15 Shionogi & Co., Ltd. Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体
AU2009213453B2 (en) 2008-02-14 2014-06-19 Gene Techno Science Co., Ltd. Anti-ADAM-15 antibodies and utilization of the same
DK2271668T3 (da) 2008-03-24 2018-03-05 Salman Rahman Adam-15-antistoffer og immunogene peptider

Also Published As

Publication number Publication date
US20150274842A1 (en) 2015-10-01
WO2009118660A4 (en) 2010-04-15
US9040049B2 (en) 2015-05-26
EP2271668B1 (en) 2017-12-20
US20110117090A1 (en) 2011-05-19
WO2009118660A2 (en) 2009-10-01
WO2009118660A3 (en) 2010-02-25
EP2271668A2 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
Tchaicha et al. Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin
Zhao et al. Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147
US20130273057A1 (en) Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
US20110212091A1 (en) Materials and methods for inhibiting cancer cell invasion
US20150274842A1 (en) Adam-15 antibodies and immunogenic peptides
Zhou et al. Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis
EP2723350B1 (en) New uses of nanog inhibitors and related methods
ES2429131T3 (es) Uso de la proteína estimulante del crecimiento KIAA1524
JP2015133984A (ja) Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法
US20210087247A1 (en) Mps peptides and use thereof
Cepeda et al. The cytoplasmic domain of MT1-MMP is dispensable for migration augmentation but necessary to mediate viability of MCF-7 breast cancer cells
HK1152535A (en) Adam-15 antibodies and immunogenic peptides
HK1152535B (en) Adam-15 antibodies and immunogenic peptides
KR20070083640A (ko) Ｅ2―ｅｐｆ5, 신규한 치료학적 단백질 및 표적
ES2728250T3 (es) Compuestos que inhiben la señalización de CD95 para el tratamiento del cáncer pancreático
IT202000031838A1 (it) Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
US9107936B2 (en) Antagonists of GRASP55 for use as a medicament
Nevo Novel Players in the Integrin Signaling Orchestra: TCPTP and MDGI
JP2010516228A (ja) タンパク質複合体および使用
Schooley Function of the cell surface receptor component integrin beta1 in human tumour cells
Odutola Preclinical Characterization of Small Molecule Compounds as Therapeutics for Cancer and Chagas' Disease: Tumor Vascular Disrupting Agents and Cysteine Protease Inhibitors
Hector-Greene The Role of Type III Transforming Growth Factor-β Receptor in Regulating ALK1
IT201800007726A1 (it) Nuova isoforma della molecola di adesione L1 della superficie cellulare avente elevata attività angiogenica.
Zajac GPR54 Transactivates EGFR to Promote Breast Cancer Cell Invasiveness
Zhang S100A10 regulates proteases activiation in colorectal cancer cells